Connect with a sales representative
Now Approved for CIDP Maintenance

In adults with chronic inflammatory demyelinating polyneuropathy

Learn about Hizentra for CIDP maintenance
For pediatric* and adult patients with primary humoral immunodeficiency

Proven. Personalized. Leader.

Proven: Efficacy & Tolerability

In addition to the US pivotal trial that confirmed the efficacy, safety, and tolerability of Hizentra, an extension study for an additional 1.7 years provided long-term data on this patient population.1,2

Review study results

Personalized: Therapeutic Options

Hizentra enables you to create personalized treatment plans to meet your patients' clinical needs and personal preferences. Dosing regimens can range anywhere from daily to once every 2 weeks.

Explore individualized therapy

Leader: The #1 Ig Prescribed for PI3

Hizentra has delivered safe and effective subcutaneous Ig (SCIg) since 2010 and has over 70,000 patient-years of experience.3 CSL Behring also offers IgIQSM, our support center for those involved with CSL Behring Ig therapy.

Learn about IgIQ support
*Age 2 and older.

Important Information for Healthcare Professionals

Below are areas you may find especially helpful when providing Hizentra to your patients.

Dosing calculation Patient resources Nurse training
Find Out More About Hizentra Connect with a sales representative
You are now leaving the current website.

Do you want to continue?

No Yes